title: Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes.
abstract: The concentrative pyrimidine-preferring nucleoside transporter 1 (hCNT1), cloned from human fetal liver, was expressed in Xenopus laevis oocytes. Using the two-electrode voltage-clamp technique, it is shown that translocation of nucleosides by this transporter generates sodium inward currents. Membrane hyperpolarization (from -50 to -150 mV) did not affect the K(0.5) for uridine, although it increased the transport current approximately 3-fold. Gemcitabine (a pyrimidine nucleoside-derived drug) but not fludarabine (a purine nucleoside-derived drug) induced currents in oocytes expressing the hCNT1 transporter. The K(0.5) value for gemcitabine at -50 mV membrane potential was lower than that for natural substrates, although this drug induced a lower current than uridine and cytidine, thus suggesting that the affinity binding of the drug transporter is high but that translocation occurs more slowly. The analysis of the currents generated by the hCNT1-mediated transport of nucleoside-derived drugs used in anticancer and antiviral therapies will be useful in the characterization of the pharmacological profile of this family of drug transporters and will allow rapid screening for uptake of newly developed nucleoside-derived drugs.
authors.affiliation: Departamento de Fisiologia y Nutrición, Universidad de Navarra, Pamplona, Spain.
authors.forename: M P
authors.initials: MP
authors.lastname: Lostao
authors.forename: J F
authors.initials: JF
authors.lastname: Mata
authors.forename: I M
authors.initials: IM
authors.lastname: Larrayoz
authors.forename: S M
authors.initials: SM
authors.lastname: Inzillo
authors.forename: F J
authors.initials: FJ
authors.lastname: Casado
authors.forename: M
authors.initials: M
authors.lastname: Pastor-Anglada
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000378:metabolism; D000970:Antineoplastic Agents / Q000378:metabolism*; D000998:Antiviral Agents / Q000378:metabolism; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D003562:Cytidine / Q000378:metabolism; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000378:metabolism; D004553:Electric Conductivity; D015870:Gene Expression; D006801:Humans; D008564:Membrane Potentials; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D033703:Nucleoside Transport Proteins; D009705:Nucleosides / Q000378:metabolism*; D009865:Oocytes / Q000378:metabolism; D012964:Sodium / Q000378:metabolism; D013379:Substrate Specificity; D014529:Uridine / Q000378:metabolism; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000378:metabolism; D014982:Xenopus laevis; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D002352:Carrier Proteins; D008565:Membrane Proteins; D033703:Nucleoside Transport Proteins; D009705:Nucleosides; D003841:Deoxycytidine; D003562:Cytidine; D012964:Sodium; D014740:Vidarabine; C024352:fludarabine; D014529:Uridine; D000093542:Gemcitabine